Global Newswire by Notified: M&A

JANUARY 3, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 45

Pharmaceutical Securities 45

Cooley M&A

JULY 10, 2017

Therefore, buyers should be cognizant of these securities law considerations and some of their practical implications. If the right to be paid contingent consideration is transferable, that right will likely be considered a “security” of the buyer under long-held SEC guidance. Private placement. earn-out rights).

Securities 52

Securities IT Investors M&A 52

Global Newswire by Notified: M&A

JANUARY 16, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 15, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 11, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 8, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 5, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 4, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 2, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 29, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 27, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 22, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 21, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 20, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 19, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 18, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 15, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 14, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 13, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 12, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 11, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 8, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 7, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 6, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 5, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 4, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 1, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 29, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 28, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 27, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 24, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 23, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 22, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 20, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 17, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 16, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 15, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40